Testosterone Therapy and Its Monitoring in Adolescent Boys with Hypogonadism: Results of an International Survey from the I-DSD Registry

STANCAMPIANO, MARIANNA R.; LUCAS-HERALD, ANGELA K.; BRYCE, JILLIAN; RUSSO, GIANNI; BARERA, GRAZIANO; BALSAMO, ANTONIO; BARONIO, FEDERICO; BERTELLONI, SILVANO; VALIANI, MARGHERITA; COOLS, MARTINE; TACK, LLOYD J.W.; DARENDELILER, FEYZA; POYRAZOGLU, SUKRAN; GLOBA, EVGENIA; GRINSPON, ROMINA; HANNEMA, SABINE E.; HUGHES, IEUAN A.; TADOKORO-CUCCARO, RIEKO; THANKAMONY, AJAY; IOTOVA, VIOLETA; MLADENOV, VILHELM; KONRAD, DANIEL; MAZEN, INAS; NIEDZIELA, MAREK; KOLESINSKA, ZOFIA; NORDENSTRÖM, ANNA; AHMED, S. FAISAL

SEXUAL DEVELOPMENT

KARGER

Año: 2021

1661-5425

It is unclear whether testosterone replacement therapy (TRT) in adolescent boys, affected by a range of endocrine diseases that may be associated with hypogonadism, is particularly common. The aim of this study was to assess the contemporary practice of TRT in boys included in the I-DSD Registry. All participating centres in the I-DSD Registry that had boys between 10 and 18 years of age and with a condition that could be associated with hypogonadism were invited to provide further information in 2019. Information on 162 boys was collected from 15 centres that had a median (range) number of 6 boys per centre (1.35). Of these, 30 (19%) from 9 centres were receiving TRT and the median (range) age at the start was 12.6 years (10.8-16.2), with 6 boys (20%) starting at